Researchers tested a new drug used to treat Hodgkin lymphoma, and found that if it was given immediately after a stem cell transplant, it makes the patients survive without the disease progressing for twice as long as those given placebo helped them.
The findings of a phase 3 trial of brentuximab vedotin (BV), the first new drug for Hodgkin lymphoma in over 30 years, are potentially practice changing for this young cancer population who have exhausted other treatment options and for whom prognosis is poor.
Follicular Lymphoma Patients May Benefit From Combination Therapy
A high risk group of patients with follicular lymphoma may benefit from a novel drug combination, a new study has found
Advertisement
Lead author Professor Craig Moskowitz said that no medication available today has had such dramatic results in patients with hard-to-treat Hodgkin lymphoma, which is the most common blood cancer in young adults aged between 15 and 35 years.
In the AETHERA phase 3 trial, Moskowitz and colleagues aimed to establish whether early treatment with BV after ASCT could prevent disease progression. They randomly assigned 329 patients with Hodgkin lymphoma aged 18 or older who were at high risk of relapse or progression after ASCT to 16 cycles of BV infusions once every 3 weeks or placebo.
![MRI Detects Breast Cancer Early in At-risk Survivors of Female Hodgkin Lymphoma]( "MRI Detects Breast Cancer Early in At-risk Survivors of Female Hodgkin Lymphoma")
MRI scans detected invasive breast tumours at early stages in female survivors of Hodgkin lymphoma at an increased risk of breast cancer, a new study has found
At 2 years follow up, the cancer had not progressed at all in 65 percent of BV patients compared with 45 percent in the placebo group.
BV was generally well tolerated. The most common side effects were peripheral neuropathy (numbness or pain in the extremities due to nerve damage) and neutropenia (low white blood count).
The study is published in The Lancet.
Source: ANI
MRI Detects Breast Cancer Early in At-risk Survivors of Female Hodgkin Lymphoma
MRI scans detected invasive breast tumours at early stages in female survivors of Hodgkin lymphoma at an increased risk of breast cancer, a new study has found
Advertisement
At 2 years follow up, the cancer had not progressed at all in 65 percent of BV patients compared with 45 percent in the placebo group.
BV was generally well tolerated. The most common side effects were peripheral neuropathy (numbness or pain in the extremities due to nerve damage) and neutropenia (low white blood count).
The study is published in The Lancet.
Source: ANI
Non-Hodgkin Lymphoma Gets Easier to Treat With a New Drug
With repeated relapse among patients and the disease becoming resistant to therapy, indolent and slow-growing non-Hodgkin lymphoma is now getting difficult to deal with
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Drug News
India's First Urinary Incontinence Drug Fesobig may offer Affordable treatment for Overactive Bladder (OAB), a widely prevalent problem among Indian men and women.
Oral anticoagulant drugs, particularly Rivaroxaban presented superior efficacy and safety than warfarin in atrial fibrillation patients with chronic kidney disease.
Patients with hepatitis D virus-related chronic advanced liver disease are treated with an antiviral therapy.
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.
Lilly will likely maintain or increase its market share in the insulin space as the average out-of-pocket cost for its insulin products is already below the $35 price cap.